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Introduction
Hypertension is a serious public health problem that affects 
almost all organs in the body and is associated with significant 
morbidity and mortality. It is an important accompanying risk fac-
tor in majority of patients with chronic kidney disease (CKD) and 
cardiovascular diseases (CVD), such as ischemic heart disease, 
cerebrovascular disease, and peripheral vascular disease (1). 
However, in a significant proportion of patients with hyperten-
sion, especially those at early stages, no obvious signs or symp-
toms of CV or renal disease are observed. Those patients might 
be truly asymptomatic despite the presence of occult organ 
damage such as micro albuminuria, left ventricular hypertrophy, 
and carotid intimae thickening (2). The asymptomatic target or-
gan damage (AOD) may actually represent an intermediate stage 
between hypertension and vascular disease. Identification of an 
AOD helps to stratify the overall CVD risk and guides a treatment 
decision in hypertensive patients (3, 4). It was hypothesized that, 
along with other factors, endothelial dysfunction may present as 
a proceeding factor in the pathogenesis of hypertension. How-
ever, endothelial dysfunction may serve as a link between hyper-
tension and AOD (5, 6).
The endothelial-cell-specific molecule-1 (ESM-1), or endo-
can, is a soluble proteoglycan (50 kDa), secreted by human vas-
cular endothelial cells and is involved in the regulation of major 
endothelial processes such as cell adhesion, migration, prolif-
eration, and neovascularization (7). Its secretion is increased in 
a variety of endothelium-dependent pathological states, such as 
inflammation, cancer, infections, and atherosclerosis. Growing 
evidence suggests that endocan is a potential endothelial cell 
marker representing the immuno-inflammatory activation of en-
dothelium (8). Celık et al. (9) have shown that the serum endocan 
level is increased in drug-naive hypertensive patients, which in 
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turn decreased by the antihypertensive treatment. It was dem-
onstrated that hypertensive patients with coronary artery dis-
ease (CAD) had a significantly higher serum endocan level than 
those without CAD and that it was correlated with the presence 
and severity of CAD (10).
Elevated levels of serum endocan have repeatedly been shown 
in hypertensive patients, especially those with symptomatic CVD 
(11) or CKD (12). However, there is paucity of data on the endocan 
levels in the asymptomatic vascular stages of hypertension. Thus, 
in the present study, we aimed to investigate the endocan levels in 
hypertensive patients without symptomatic CVD or CKD. In addi-
tion, we sought the relationship between the endocan levels and 
the presence and extent of AOD in hypertensive patients.
Methods
The present study was carried out at the Sakarya Univer-
sity Training and Research Hospital, Cardiology Clinic from June 
2016 to October 2017. The study was performed in accordance 
with the Declaration of Helsinki, and the study protocol was ap-
proved by the Medical Research Ethics Committee of Sakarya 
University, Faculty of Medicine. All the patients provided written 
informed consent to participate in the study.
Study population
Patients who were admitted to our outpatient cardiology 
clinic and diagnosed with systemic hypertension were pro-
spectively enrolled to present study according to prespecified 
inclusion and exclusion criteria. The inclusion criterion was the 
presence of systemic arterial hypertension in subjects older 
than 18 years. The following patients were excluded from the 
study: those with secondary hypertension, diabetes mellitus, 
chronic kidney disease stage ≥3, symptomatic CVD (those who 
had documented coronary artery disease, cardiac failure, valvu-
lar heart disease, peripheral arterial disease, and cerebrovas-
cular disease). Patients who had suggestive symptoms or signs 
of CVD and needed further evaluation were also excluded from 
the study. After exclusion, a total of 132 eligible patients met the 
criteria and were consecutively enrolled to the study.
Clinical variables and definitions
We carried out a complete clinical history and CV examina-
tion in all participants with particular emphasis on personal CV 
risk factors. Clinical variables included age, smoking status, a 
family history of CAD, presence of hypercholesterolemia, body 
mass index (BMI), waist circumference, and systolic and dia-
stolic blood pressures. Hypertension was defined as a systolic 
BP (SBP) of >140 mm Hg and/or a diastolic BP (DBP) of >90 mm 
Hg (the mean of 3 measurements at ≥ 2 visits) or current use of 
an antihypertensive medication. Likewise, hypercholesterolemia 
was defined as the presence of total serum cholesterol levels 
greater than 200 mg/dL or the use of lipid-lowering agents.
The following six parameters were studied and considered to 
be the indicators of AOD (4): a) the pulse pressure ≥60 mm Hg; 
b) electrocardiographic left ventricular hypertrophy (LVH) (So-
kolow–Lyon index >3.5 mV; RaVL >1.1 mV; Cornell voltage duration 
product >244 mV*ms) or echocardiographic LVH (left ventricular 
mass index: men >115 g/m2, women >95 g/m2); c) carotid wall thick-
ening [intimae-media thickness (CIMT) >0.9 mm] or plaque; d) the 
ankle-brachial index (ABI) <0.9; e) arterial stiffness indicated by 
the cardio-ankle vascular index (CAVI) >8; f) CKD with estimated 
glomerular filtration rate (eGFR) 30–60 mL/min/1.73 m2.
Biochemical measurements
Blood samples were collected in the morning following a 
12-hour fasting. Samples for routine biochemical tests such as 
the fasting blood glucose, creatinine, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), total cholesterol, low 
density lipoprotein cholesterol, high density lipoprotein choles-
terol, and triglycerides were studied in the Central Biochemistry 
Laboratory of Sakarya University Training and Research Hos-
pital, using standard laboratory techniques. For endocan mea-
surement, a 10 mL blood sample was immediately centrifuged 
for 10 minutes to separate the plasma and serum, and serum was 
stored at –80°C until analyzed. The endocan levels were mea-
sured using an enzyme-linked immunosorbent assay (Abbkine 
Scientific Co., Ltd. Bldg 1, No.35, Optical Valley Ave, California, 
USA), in accordance with the manufacturers’ instructions. 
Assessment of asymptomatic target organ damage 
The pulse pressure was calculated by subtracting the systolic 
arterial pressure from diastolic arterial pressure. A value ≥60 mm 
Hg was considered abnormal, indicating loss of the elasticity in 
aorta. The arterial stiffness and ABI measurements were obtained 
in a quiet, temperature-controlled room after 10 min at rest with 
patient in the supine position, according to the recommendations. 
CAVI and ABI were measured with a VeSera VS-2000 instrument 
(Fukuda Denshi Co. Ltd., Tokyo, Japan) by the methods previously 
described (13). Briefly, a cuff was applied to bilateral upper arms 
and ankles with subject in the supine position and head held in 
the mid-line position. Then, the phonocardiography microphone 
and electrocardiography (ECG) electrodes were placed. After 
resting for 10 min, the VeSera VS-2000 measured extremity blood 
pressures and calculated the CAVI and ABI automatically. A CAVI 
value ≥8 was used to define abnormal level of arterial stiffness 
(13). An ABI value <0.9 was considered abnormal and an indicator 
for asymptomatic peripheral arterial disease. 
The LVH was assessed using ECG and echocardiography. The 
following ECG criteria were used to detect LVH: the Sokolow–
Lyon index (S wave in V1+R wave V5 >3.5 mV), the modified So-
kolow–Lyon index (largest S-wave+largest R-wave >3.5 mV), R 
wave in aVL >1.1 mV, or Cornell voltage QRS duration product 
>244 mV*ms. The Cornell voltage QRS duration product is cal-
culated by multiplying the Cornell voltage sum (R wave in aVL+S 
wave in V1) by the duration of the QRS complex. Echocardiogra-
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phy was performed by an investigator blinded to each patient’s 
clinical status, using a commercial echocardiography machine 
(Philips IE33, Andover, MA, USA) equipped with a 2.5 MHz phased 
array transducer. Complete 2D, color, pulsed, and continuous-
wave Doppler examinations were performed according to stan-
dard techniques. The calculation of the LVMI was performed ac-
cording to the American Society of Echocardiography formula (14). 
Thresholds of 95 g/m2 for women and 115 g/m2 (body surface area) 
for men were used for estimates of clear-cut LVH.
Carotid ultrasonography was performed with an Aplio MX 
unit (Toshiba Medical Systems Co, Ltd, Tokyo, Japan) equipped 
with a 7.5 MHz linear array imaging probe. The right common 
carotid artery (CCA) was examined with the patient lying in the 
supine position, the head directed away from the side of interest 
and the neck extended slightly. The transducer was manipulated 
so that the near and far walls of the CCA were parallel to the 
transducer footprint, and the lumen diameter was maximized in 
the longitudinal plane. A region 1 cm proximal to the carotid bi-
furcation was identified, and the CIMT of the far wall was evalu-
ated as the distance between the lumen–intimae interface and 
the media–adventitia interface. The CIMT measurement was 
obtained from four contiguous sites at 1 mm intervals, and the 
average of the four measurements was used for analyses. All 
measurements were performed by the same investigator (Y.G.) 
without the knowledge of clinical data and study protocol.
The glomerular filtration rate (GFR) was estimated and in-
dexed according the MDRD formula (15). An estimated GFR val-
ue of 30–60 mL/min/1.73 m2 was considered to be an indicator of 
asymptomatic kidney damage. 
Statistical analysis
Data are expressed as mean±standard deviation (SD) for 
normally distributed continuous variables, as median and inter-
quartile ranges for skew-distributed continuous variables, and as 
frequencies for categorical variables. Participants were dichoto-
mized according to having at least one AOD marker. Comparisons 
were performed in the AOD (+) and AOD (–) groups. The Pearson 
chi-squared test was used to compare categorical variables. The 
means for normally distributed continuous variables were com-
pared by independent-samples t-test. Skew-distributed continu-
ous variables were compared using a Mann–Whitney U-test. Like-
wise, serum endocan levels were compared for any independent 
AOD marker. The correlation between the serum endocan level 
and pulse pressure, CIMT, ABI, CAVI, LVMI, Sokolow-Lyon index, 
Cornell voltage QRS duration product, and eGFR were assessed 
using Pearson’s or Spearman’s correlation coefficient.
It was hypothesized that the serum endocan level would be 
higher in the AOD (+) group. Careful review of literature revealed 
no referent values for endocan in asymptomatic hypertensive 
patients, specifically evaluating the levels at pre-AOD and post-
AOD stages. Thus, it was not possible to gauge the effect size 
based on previous reports. With the assumption of the medium 
effect size of 0.5 and a Type I error of 5%, the study required ap-
proximately 102 patients to yield a statistical power of 80%. Sta-
tistical analyses were performed with the SPSS software (ver-
sion 15.0 for Windows; SPSS Inc., Chicago, IL, USA). The power 
and sample size analysis was performed with the G*Power soft-
ware (version 3.1.9.2 for Windows; The G*Power Team: Axel Bu-
chner, Edgar Erdfelder, Franz Faul, Albert-Georg Lang, Heinrich 
Heine University Dusseldorf, Germany).
Results
The study included 132 patients. The majority of patients 
were women (82 female, 50 male), and the mean age was 50±9 
years. The number of patients in different hypertension stages 
were as follows: 20 patients (15%) were at Stage 1, 79 patients 
(60%) were at Stage 2, and 33 patients (25%) were at Stage 3. 
The number of patients who were receiving an antihypertensive 
medication was 114 (86%). The frequency of patients with differ-
ent AOD markers is presented in Table 1. 
Table 1. Frequency of patients with different asymptomatic target organ damage markers
 Asymptomatic target organ damage n %
1 Pulse pressure ≥60 mm Hg 38 28.8
2 Electrocardiographic LVH (Sokolow–Lyon index >3.5 mV; RaVL 58 43.9
 >1.1 mV; Cornell voltage duration product >244 mV*ms) or                                                         63                                                  47.7
 Echocardiographic LVH (LVM index: men >115 g/m2; 9 6.8
 women >95 g/m2 [BSA]) 
3 Carotid wall thickening (CIMT >0.9 mm) or plaque 32 24.2
4 Ankle-brachial index <0.9 5 3.8
5 Cardio-ankle vascular index (CAVI) >8 51 38.6
6 CKD with eGFR 30-60 mL/min/1.73 m2 0 0
AOD - asymptomatic target organ damage; BSA - body surface area; CAVI - cardio-ankle vascular index; CIMT - carotid intimae-media thickness; CKD - chronic kidney disease; LVH - 
left ventricular hypertrophy; LVM - left ventricular mass
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Patients were rated according to the AOD load. With respect 
to studied parameters, it is theoretically possible that the AOD 
load could be rated 0 to 6. Thirty-one patients (23.5%) were AOD 
free; however, 101 patients had at least one AOD. In 4 patients, 4 
different AOD markers were present at the same time. None of 
the patients had 5 or 6 AOD at the same tame (Table 2). 
Clinical and laboratory characteristics of subjects with and 
without AOD were summarized in Table 3. Male gender frequen-
cy (44.5% vs. 16%, p=0.005) was higher in patients with AOD. Due 
to close relation of some parameters with AOD, we found higher 
systolic, diastolic, and pulse pressures and higher CIMT and 
CAVI values in patients with AOD. Likewise, the Skolow–Lyon 
and LVM indices were higher in patients with AOD. Among other 
echocardiographic parameters, E wave, e’ wave, E/A, and GLS 
were lower in the AOD group. There were no significant differ-
ences with respect to lipid parameters; however, creatinine and 
AST levels were higher in the AOD group. Interestingly, serum 
endocan levels did not differ between the groups (3.81±0.78 vs. 
3.83±0.63 ng/mL, p=0.88). 
Analyses of serum endocan levels, depending on the pres-
ence or absence of a specific AOD, showed no difference be-
tween groups (Table 4). The relationship between the serum en-
docan level and other continuous AOD variables was assessed 
by the correlation analysis. The serum endocan level did not 
significantly correlate with any of the variables such as pulse 
Table 2. Frequency of patients according to asymptomatic 
target organ damage load









Table 3. Clinical and laboratory characteristics of patients 
with and without asymptomatic target organ damage
 AOD + AOD – P value
 (n=101) (n=31)
Gender (Male/Female) 45/56 5/26 0.005
Age, years 51.2±9.5 48.2±8.1 0.11
BMI, kg/m2 30.0±4.6 30.4±4.4 0.64
Waist circumference, cm 99.4±11.4 96.1±11.2 0.16
Family history for CAD, n (%) 11 (10.9) 3 (9.7) 0.84
Current smokers, n (%) 30 (29.7) 6 (19.4) 0.26
Antihypertensive drug  89 (88.1) 25 (80.6) 0.29
use (%)
Systolic blood 145±12 132±8 <0.0001
pressure, mm Hg
Diastolic blood 86±8 80±8 <0.0001
pressure, mm Hg
Pulse pressure*, mm Hg 52/57/63 49/50/54 <0.0001
ECG parameters
Skolow–Lyon index, mV 3.8±2 2.2±1.1 <0.0001
RaVL*, mV 0.3/0.5/0.6 0.3/0.4/0.7 0.92
Cornell voltage duration 116±56 96±45 0.07
product, mV*msn
Echocardiographic parameters
LVEF, % 60.7±4.0 62.2±3.6 0.06
E wave, cm/sec 69.0±16.3 75.7±15.6 0.04
A wave, cm/sec 76.4±20.1 70.3±19.2 0.14
E/A*  0.68/0.83/1.21 0.81/1.23/1.41 0.01
Septal e’ wave, cm/sec 6.7±1.6 7.8±1.6 0.002
E/e’ * 8.7/10.1/11.5 8.4/9.9/11.2 0.45
GLS, % 18.9±4.1 22.5±3.3 <0.0001
LVMI, gr/m2 81±18 67±13 <0.0001
Table 3. Cont.
 AOD + AOD – P value
 (n=101) (n=31)
Biochemical parameters
Fasting blood glucose, mg/dL 101±12 99±12 0.57
Creatinine, mg/dL 0.76±0.16 0.66±0.13 0.001
eGFR*, mL/min/1.73 m2 93/98/101 97/100/108 0.007
ALT*, u/L 17/23/32 14/18/32 0.06
AST*, u/L 19/21/27 16/19/22 0.05
Total cholesterol, mg/dL 206±38 211±44 0.52
Triglyceride*, mg/dL 93/145/188 102/146/245 0.51
HDL, mg/dL 46±14 47±12 0.62
LDL, mg/dL 137±32 142±42 0.45
Endocan, ng/mL 3.81±0.78  3.83±0.63  0.88
CIMT*, mm 0.5/0.8/1 0.4/0.6/0.7 <0.0001
ABI 1.03±0.09 1.02±0.08 0.45
CAVI 7.8±1.3 7.0±0.8 0.001
*Skew-distributed continuous variables were expressed as 25th, median and 75th 
percentiles.
ABI - ankle-brachial index; ALT - alanine aminotransferase, AST - aspartate 
aminotransferase; AOD - asymptomatic target organ damage; BMI - body mass index; 
CAD - coronary artery disease; CAVI - cardio-ankle vascular index; CIMT - carotid 
intima-media thickness; eGFR - estimated glomerular filtration rate; GLS - global 
longitudinal strain; HDL - high-density lipoprotein; LDL - low-density lipoprotein; LVEF - 
left ventricular ejection fraction; LVMI - left ventricular mass index
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pressure, the CIMT, CAVI, ABI, LVMI, Sokolow–Lyon index, Cor-
nell voltage duration product, and eGFR. 
A post-hoc power analysis revealed that the study achieved 
78% power to demonstrate an effect size of 0.5, with a corre-
sponding Type I error of 5%.
Discussion
In our study, no significant difference in endocan levels was 
found in asymptomatic hypertensive patients with or without 
AOD. In addition, serum endocan levels did not correlate with 
any of the variables related to AOD. Our results suggest that en-
docan does not possess adequate usefulness as a surrogate 
biochemical marker for the presence of AOD in hypertensive 
individuals. To the best of our knowledge, this is the first study 
to evaluate the relationship of endocan with any specific AOD 
in hypertensive individuals without symptomatic CVD and CKD.
Hypertension is an important risk factor for several CV 
events such as stroke, myocardial infarction, sudden mortality, 
heart failure, peripheral arterial disease, as well as end-stage 
renal disease (1). The estimation of the total CV risk in a hyper-
tensive individual is relatively easy in a particular subgroup of 
patients with established CVD, CKD or diabetes. In such patient 
subgroups, management is relatively straightforward, including 
intensive CV risk-reducing measures along with an antihyper-
tensive medication (4). However, a large number of patients with 
hypertension are truly asymptomatic and do not belong to any 
of the above categories, yet may deserve specific therapeutic 
interventions. In such clinical scenario, identification of occult 
target organ damage helps clinician to stratify total CV risk ap-
propriately (2, 3). AOD represents an intermediate stage between 
hypertension and vascular disease that requires additional tests 
for identification. Carotid ultrasound, ECG/echocardiography, 
and applanation tonometry are some of laboratory tools for the 
identification of AOD, with specific thresholds for carotid intimal 
thickening, LV hypertrophy, and pulse velocity (3). Asymptomatic 
kidney damage can readily be identified with simple biochemical 
tests, such as eGFR and microalbuminuria. 
Endothelial dysfunction has been shown to be related to hy-
pertension in a number of studies conducted on hypertensive 
patients and different animal models (5). Vascular alterations 
associated with hypertensive phenotype, such as vascular re-
modeling, increased peripheral vascular resistance, decreased 
synthesis of vasodilators, and inflammation, all share endothe-
lial dysfunction as a common denominator (6). Vascular theory 
on the pathogenesis of hypertension has opened the way for 
the study of various biochemical markers related to endothelial 
functions. Among them, ESM-1 (endocan) has recently gained 
clinical attention. Balta et al. (16) have studied the endocan lev-
els in hypertensive patients and reported higher endocan levels 
compared to healthy control group. Similarly, Celık et al. (9) have 
shown that the serum endocan level is higher in drug-naive hy-
pertensive patients, which in turn decreased after the initiation of 
antihypertensive treatment. In the further researches, increased 
levels of serum endocan have consistently been shown in vari-
ous disease states related to immuno-inflammatory activation 
of endothelium, such symptomatic CAD (10), CKD (12), psoriasis 
vulgaris (17), Behçet’s disease (18), familial Mediterranean fever 
(19), SLE (20), and sarcoidosis (21). However, data, specifically 
evaluating the endocan levels in AOD stage of hypertension, are 
relatively scarce. In the present study, we systemically searched 
various AOD markers and analyzed endocan levels according 
to the presence and absence a specific AOD marker in patients 
belonging to the asymptomatic vascular stages of hypertension. 
We found no difference in endocan levels in patients with ca-
rotid intimae-media thickening, which was one of our interests. 
Similarly, no significant correlation was found in serum endocan 
Table 4. Serum endocan level depending on presence or absence of specific asymptomatic target organ damage
                                                              Endocan level, ng/mL  P value
Asymptomatic target organ damage parameters (+) (-)
Pulse pressure >60 mm Hg 3.8±0.8 3.8±0.7 0.72
Electrocardiographic LVH (Sokolow–Lyon index  3.7±0.8 3.9±0.7 0.07
>3.5 mV; RaVL >1.1 mV; Cornell voltage duration 
product >244 mV*ms) or Echocardiographic 
LVH [LVM index: men >115 g/m2; women >95 g/m2 (BSA)]
Carotid wall thickening (CIMT >0.9 mm) or plaque 3.8±0.8 3.8±0.7 0.90
Ankle-brachial index <0.9 3.7±0.8 3.8±0.7 0.72
Cardio-ankle vascular index (CAVI) >8 3.8±0.8 3.8±0.7 0.69
CKD with eGFR 30–60 mL/min/1.73 m2 - 3.8±0.7 -
BSA - body surface area; CAVI - cardio-ankle vascular index; CIMT - carotid intimae-media thickness; CKD - chronic kidney disease; LVH - left ventricular hypertrophy; LVM - left 
ventricular mass
Ağaç et al.
Endocan as a marker for asymptomatic organ damage
Anatol J Cardiol 2019; 21: 76-82
DOI:10.14744/AnatolJCardiol.2018.25564 81
levels and CIMT. The published data indicate positive correla-
tions between serum endocan and CIMT in various disease 
states such astype 2 diabetes (22), CKD (12), psoriasis vulgaris 
(17), and SLE (20). The results of those studies are not com-
parable to the present study due to the inclusion of a different 
patient population. However, discordant to our results, Balta et 
al. (16) have found a positive correlation between the endocan 
level and CIMT in hypertensive patients without symptomatic 
CV disease. 
Yilmaz et al. (12) studied the endocan levels in patients with 
CKD and its association with eGFR. They found a negative cor-
relation between the endocan level and eGFR. In a study con-
ducted in renal transplant recipient patients, higher endocan 
levels were demonstrated in more advanced CKD stages in a 
dose-dependent manner (23). In the present study, we could not 
demonstrate a significant correlation between the endocan level 
and eGFR. Of note, none of our patients had eGFR less than 60 
mL/min/1.73 m2. This indicates a population with a relatively nor-
mal renal function, which might be the reason why we could not 
demonstrate a significant correlation between endocan levels 
and eGFR. Similar to the results in CIMT and eGFR, we could not 
demonstrate any significant correlation between the endocan 
levels and other continuous parameters related to AOD such as 
pulse pressure, LVMI, ABI, and CAVI. In addition, no difference 
in endocan levels was observed in case of the presence of any 
other AOD marker. Taking our consistent results and current lit-
erature into consideration, we propose that elevated endocan 
levels might be a characteristic of advanced endothelial damage, 
which coincides with symptomatic CVD and CKD. 
Study limitation
The main limitation of our study is a relatively small sample 
size. Since, we could not find published data on endocan levels 
in a study group similar to our patient population, our sample-
size estimates might have been misleading due to a presumed 
effect size of 0.5. A small sample size might obscure the subtle 
difference in endocan levels in AOD positive and negative pa-
tients. Therefore, our results should be interpreted with caution. 
The actual effect size and corresponding power of the present 
study might be lower than reported. The second limitation or our 
study is the absence of a control group. The absence of other 
biomarkers related to endothelial dysfunction can be considered 
as another limitation. 
Conclusion
In conclusion, we suggest that endocan may not serve as a 
useful biomarker at asymptomatic vascular stages of hyperten-
sion, despite its role in indicating disease severity and inflamma-
tory activation in advanced symptomatic CVD and CKD.
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